Slide 1: Regulation 30 filing cover letter
Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051 ,Telangana, India T: +91 4027264141 F: +91 40 2726 3657 VimtDriven by Quality. Inspired by Science. VLL\SE\01 2\2024-25 Date: 18.05.2024 Listing Centre Asst Vice President B S E Limited National Stock Exchange of I
Slide 2: Vimta Labs Limited Investor Presentation Q4 & FY24
Vimta Labs Limited Investor Presentation Q4 & FY24 1
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Contents
Contents Q4 & FY24 Earnings 1 Company Overview 2 Industry Landscape 3 Our Competitive Advantage 4 Way Forward 5 3
Slide 5: Q4 & FY24 Earnings
Q4 & FY24 Earnings ▪ Q4 & FY24 Highlights ▪ Key Metrics: Q4 & FY24 ▪ Profit & Loss Statement ▪ Balance Sheet ▪ Financial Track Record ▪ Shareholding Pattern 01 4
Slide 6: Q4 & FY24 Highlights
Q4 & FY24 Highlights Q4FY24 Earnings Highlights ➢ Total Income for Q4FY24 was at Rs. 802 Mn ➢ EBITDA for Q4FY24 was Rs. 249 Mn; EBITDA margin was at 31.1% ➢ Q4FY24 PAT was at Rs. 124 Mn ➢ Basic EPS in Q4FY24 was Rs. 5.6 FY24 Earnings Highlights ➢ Total Income for FY24 was at Rs. 3,223 Mn ➢ EBITDA fo
Slide 7: FY24 Operational Highlights
FY24 Operational Highlights Operational Updates Q4FY23 ➢ During the year, the company re-strategized its services portfolio providing greater impetus for driving growth in food, pharma, and electronics testing while other industry services were optimized based on their returns. ➢ Initiated long term
Slide 8: Key Metrics: Q4 & FY24
Key Metrics: Q4 & FY24 Q4FY24 SNAPSHOT Total Income1 (In ₹ Mn) EBIDTA & EBIDTA Margin1 (In ₹ Mn, %) PAT & PAT Margin1 (In ₹ Mn, %) Basic EPS (In ₹) 31% 15% 15% 12% 150 18% 250 16% 30% 225 125 5 14% 200 175 100 12% 28% 150 10% 75 125 8% 2.8% 0.3% 2.6% 100 825 826 802 50 6% 75 248 227 249 127 101 124
Slide 9: Profit & Loss Statement
Profit & Loss Statement Particulars (₹ Mn) Q4 FY24 Q4 FY23 YoY (%) Q3 FY24 QoQ(%) FY24 FY23 YoY (%) Revenue from Operations 797 818 -2.6% 817 -2.4% 3,183 3,182 0.0% Other Income 5 7 9 40 34 Total Income 802 825 -2.8% 826 -2.9% 3,223 3,216 0.2% Material and Testing Costs 176 188 197 759 718 Cost of l
Slide 10: Balance Sheet
Balance Sheet Particulars (₹ Mn) 31 March 2024 (Audited) 31 March 2023 (Audited) Assets Fixed Assets 1,564 1,570 Capital work-in-progress 586 123 Goodwill 56 56 Intangible assets 91 122 Other non-current assets 128 116 Total non current assets 2,425 1,987 Trade Receivable 870 800 Inventories 247 226
Slide 11: Financial Track Record
Financial Track Record TOTAL INCOME (₹ Mn) PROFITABILITY (₹ Mn) EBITDA & EBITDA Margin PAT & PAT Margin 29% 31% 28% 15% 15% 25% 13% 18% 4% 10% 15.1% 28.8% 56.5% 1,837 2,115 2,797 3,216 3,223 CAGR 330 538 817 984 908 CAGR 68 214 413 482 410 CAGR FY20 FY21 FY22 FY23 FY24 FY20 FY21 FY22 FY23 FY24 FY20
Slide 12: Shareholding Pattern
Shareholding Pattern Shareholding as on 31st March 2024 Share Information as on 31st March 2024 NSE Ticker VIMTALABS BSE Ticker 524394 Market Cap (INR Cr) 985.70 % free-float 63.08% Others Free-float market cap (INR Cr) 621.73 Promoters 56.5% 36.9% Total Debt (INR Mn) 192 Cash & Cash Equivalents (IN
Slide 13: Company Overview
Company Overview ▪ Vimta Labs at a Glance ▪ Our Journey ▪ Services ▪ Geographical Presence ▪ Management ▪ Accreditation 02 12
Slide 14: Vimta Labs at a Glance
Vimta Labs at a Glance Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high quality, cutting edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics
Slide 15: Our Journey
Our Journey ` ` Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & 2023 400,000+ ft2 1400+ 492 M development services; Food; 3,216 M Environment; Clinical Diagnostics; Electronics 2015 Analytical – Pharma, Biopharma & 400,000+ ft2 1000+ 580 M Food; Clinical Resear
Slide 16: Our Offerings (1/3)
Our Offerings (1/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Services Clinical Diagnostics & Consultancy to Lifesciences Electricals Testing Industry Offerings Pharma Analytical Clinical Research Preclinical Support Industry Pharmaceuticals Pharmace
Slide 17: Our Offerings (2/3)
Our Offerings (2/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Electricals Testing Clinical Diagnostics to Lifesciences Services & Consultancy Industry Offerings Food Testing Electronics & Electricals Testing No. of Laboratories 7 1 Accreditations & F
Slide 18: Our Offerings (3/3)
Our Offerings (3/3) Drug discovery and development support Food & Agriculture Electronics & Environment Testing Clinical Diagnostics to Lifesciences Services Electricals Testing & Consultancy Industry Offerings Clinical Diagnostics Environment Testing & Consultancy No. of Laboratories 2 (regional re
Slide 19: Geographical Presence
Geographical Presence Headquartered in Hyderabad, VIMTA has 19 laboratories across India, with a total laboratory space of over 400,000 sq. ft. Hyderabad (Headquarters) Food Clinical Diagnostics Pharma Electronics & Electrical Environment Food Environment Clinical Diagnostics Ahmedabad Chennai Noida
Slide 20: Key Management Team
Key Management Team S P Vasireddi Harita Vasireddi Sreenivas Neerukonda Executive Chairman Managing Director Executive Director Dr. S P Vasireddi is a Scientist – Technocrat – Harita has close to 25 years of Sreenivas’s core competencies include Entrepreneur having more than 45 years of experience i
Slide 21: Key Management Team (Cont'd)
Key Management Team (Cont’d) Harriman Vungal Suresh Kumar Narahari Naidu D.R. Executive Director - Operations President Chief Financial Officer Harriman was inducted to the Board as Suresh have more than two decades Narahari has close to 15 years of one of the Promoter Directors in 1990 of experienc
Slide 22: Industry Landscape
Industry Landscape ▪ Market Opportunity ▪ Factors Driving Industry Growth 03 21
Slide 23: Market Opportunity
Markets Opportunity Pharmaceutical & Preclinical Food Testing Clinical Testing Environment Electronics Biopharmaceuticals Testing Testing 957.6 Global 405.5 127.3 124.7 76.6 40.5 76.2 19.5 11.1 20.2 6.8 13.4 2020 | 2028 2023 | 2028 2022 | 2032 2022 | 2028 2022 | 2030 2021 | 2031 (USD bn) CAGR: 11.3%
Slide 24: Factors Driving Industry Growth
Factors Driving Industry Growth Drug Electrical & Food Environment Discovery & Electronics Diagnostics Testing Testing Development Testing Increasing demand Growing international Surge in demand for Increase in Health risks from for new drug food regulations, certification services regulations to co
Slide 25: Our Competitive Advantage
Our Competitive Advantage ▪ Our Position in the CRTO Landscape ▪ Our Strength 04 24
Slide 26: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape 1 Pharma Analytical & Preclinical 4 Food Testing #1 in India #1 in India Customers – 90% of India top 20 Customers – 70% of India top 10 36% revenues from overseas 2 Clinical Research 5 Environment Among the most reputed CROs in India Among top 5 in India 75% of re
Slide 27: Our Strengths
Our Strengths QUALITY CUSTOMER Long & successful CENTRICITY regulatory track Long term record – cGMP, GLP, partnerships with GCP customers INFRASTRUCTURE KNOWLEDGE Unparalleled lab Multi-disciplinary, infrastructure in the knowledgeable, skilled country. Gold LEED and trained manpower certified Viva
Slide 28: Way Forward
Way Forward ▪ Our Key Growth Drivers & Strategies 05 27
Slide 29: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies Favourable markets Core business strategies Core operational strategies Best practices ✓ Growth momentum ✓ Capacity expansions ✓ Operational excellence ✓ Good corporate in markets ✓ Service innovations ✓ Hiring right talent governance ✓ Growing demand ✓ Penetratio
Slide 30: Thank You
Thank You May 2024 VIMTA LABS LIMITED INVESTOR RELATIONS AT Registered Office Vimta Labs Ltd. Plot Number 142, IDA Phase 2 Narahai Naidu Dodda, CFO Cherlapally, Hyderabad Narahai.Dodda@vimta.com Telangana, India. 500051 NSE: VIMTALABS, BSE: 524394 ISIN: INE579C01029 Siddesh Chawan Advait Bhadekar We